Literature DB >> 30562845

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists.

Hitoshi Kohsaka1, Tsuneyo Mimori2, Takashi Kanda3, Jun Shimizu4, Yoshihide Sunada5, Manabu Fujimoto6, Yasushi Kawaguchi7, Masatoshi Jinnin8, Yoshinao Muro9, Shoichiro Ishihara10, Hiroyuki Tomimitsu10, Akiko Ohta11, Takayuki Sumida12.   

Abstract

Although rheumatologists, neurologists and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of the present study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time. This article has been co-published with permission in Neurology and Clinical Neuroscience, The Journal of Dermatology and Modern Rheumatology. All rights reserved.
© 2018 the Japanese Society of Neurology, the Japanese Dermatological Association and the Japan College of Rheumatology. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.

Entities:  

Keywords:  consensus; dermatomyositis; management; polymyositis; treatment

Mesh:

Substances:

Year:  2018        PMID: 30562845     DOI: 10.1111/1346-8138.14604

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  3 in total

1.  Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report.

Authors:  Maia L Valls; Adam M Kase; Rina Patel; Benjamin Wang; Rohit Aggarwal; Gerardo Colon-Otero
Journal:  Gynecol Oncol Rep       Date:  2022-05-25

2.  Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis.

Authors:  Houari Aissaoui; Kinan Drak Alsibai; Naji Khayath
Journal:  Clin Pract       Date:  2021-04-22

3.  Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study.

Authors:  Celine Miyazaki; Yutaka Ishii; Natalia M Stelmaszuk
Journal:  Clin Rheumatol       Date:  2021-10-22       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.